Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 May 10;73(6):888-889.
doi: 10.1136/gutjnl-2023-331480.

Enhancing the opportunities for cholangiocarcinoma precision therapy

Reka Toth  1 , Paul J Brindley  2 , Javier Vaquero  3
Affiliations
Comment

Enhancing the opportunities for cholangiocarcinoma precision therapy

Reka Toth et al. Gut. .
No abstract available

Keywords: cholangiocarcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1.
Figure 1.
Differential enhancer analysis of cholangiocarcinoma (CCA) tumour samples and CCA cell lines. Unsupervised clustering identified three enhancer groups in CCA with distinct enhancer profiles: the IMMUN group, the OXPHO group and the ESTRO group. Each of the enhancer groupsshowed enrichment in specific pathways that were targetable as demonstrated in vitro in cell lines and in vivo in xenograft and patient-derivedxenografts (PDX).
See this image and copyright information in PMC

Comment on

References

    1. Banales JM, et al. , Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol, 2020. 17(9): p. 557–588. - PMC - PubMed
    1. Brindley PJ, et al. , Cholangiocarcinoma. Nat Rev Dis Primers, 2021. 7(1): p. 65. - PMC - PubMed
    1. Jusakul A, et al. , Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov, 2017. 7(10): p. 1116–1135. - PMC - PubMed
    1. Sia D, et al. , Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology, 2013. 144(4): p. 829–40. - PMC - PubMed
    1. Hong JH, et al. , Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut, 2023. - PubMed

Publication types

LinkOut - more resources